RADX (Radiopharm Theranostics) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RADX Radiopharm Theranostics Ltd RADX
33 GF Score
Price $2.08
GF Value $2.34
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Radiopharm Theranostics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RADX vs VRTX, REGN, MRNA: Short Interest Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Short Interest distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Short Interest falls into.


RADX
33GF Score
Radiopharm Theranostics Ltd RADX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Radiopharm Theranostics (RADX) Overvalued in 2026?

Based on GuruFocus' analysis, Radiopharm Theranostics stock appears to be undervalued. The current stock price of $2.08 is trading 11.1% below its estimated GF Value™ of $2.34. GuruFocus considers Radiopharm Theranostics to be Modestly Undervalued.

Key valuation signals for RADX:

  • Short Interest:
  • GF Value™: $2.34 vs. price of $2.08 (11.1% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the RADX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Radiopharm Theranostics Business Description

Other Exchanges RAD:Australia
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
33GF Score

Get the complete analysis for RADX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$2.34
GF Value